Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001403525 XXXXXXXX LIVE 12 Common Shares, no par value 05/01/2026 false 0000351834 8676EP108 SunOpta Inc. 7078 SHADY OAK ROAD EDEN PRAIRIE MN 55344 Richard Ting (213) 830-6300 Oaktree Capital Group Holdings GP, LLC 333 South Grand Avenue, 28th Floor Los Angeles CA 90071 Y Oaktree Organics, L.P. b OO N DE 0 0 0 0 0 N 0 PN Y Oaktree Huntington Investment Fund II, L.P. b OO N DE 0 0 0 0 0 N 0 PN Y Oaktree Capital Holdings, LLC b N DE 0 0 0 0 0 N 0 OO 0001403525 N Oaktree Capital Group Holdings GP, LLC b N DE 0 0 0 0 0 N 0 OO Common Shares, no par value SunOpta Inc. 7078 SHADY OAK ROAD EDEN PRAIRIE MN 55344 This Amendment No. 12 ("Amendment No. 12") amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission on October 17, 2016, as amended by Amendment No. 1 through Amendment No. 11 (as so amended, the "Schedule 13D"). Except as set forth herein, the Schedule 13D remains in full force and effect. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Schedule 13D. Item 4 of the Schedule 13D is hereby amended and supplement to add the following at the end thereof: In connection with consummation on May 1, 2026, of the transactions contemplated by the Arrangement ("Closing"): (i) each share of Series B-1 Preferred Stock was transferred to the Issuer in exchange for the number of Common Shares calculated by multiplying the number of shares of Series B-1 Preferred Stock by 405.9555467 (being the exchange rate of the Series B-1 Preferred Stock contemplated by their terms); (ii) each Common Share was transferred to Purchaser for consideration of $6.50 in cash and (iii) each issued and outstanding Special Share, Series 2 was cancelled without any payment in respect thereof. Following Closing, the Common Shares ceased to be listed or traded on NASDAQ, and the Issuer became a privately-held company. The information relating to the beneficial ownership of Common Shares by each of the Reporting Persons set forth in rows (11) and (13) of the cover pages hereto is incorporated by reference into this Item 5(a). The information relating to the beneficial ownership of Common Shares by each of the Reporting Persons set forth in rows (7) through (10) of the cover pages hereto is incorporated by reference into this Item 5(b). The information set forth in Item 4 hereof is incorporated by reference into this Item 5(c). Not Applicable. After giving effect to Closing, the Reporting Persons ceased to beneficially own any Issuer securities. Oaktree Organics, L.P. /s/ Zachary Serebrenik Zachary Serebrenik / Managing Director 05/05/2026 Oaktree Huntington Investment Fund II, L.P. /s/ Zachary Serebrenik Zachary Serebrenik / Managing Director 05/05/2026 Oaktree Capital Holdings, LLC /s/ Henry Orren Henry Orren / Managing Director 05/05/2026 Oaktree Capital Group Holdings GP, LLC /s/ Henry Orren Henry Orren / Managing Director 05/05/2026 OAKTREE ORGANICS, L.P., By: Oaktree Fund GP, LLC Its: General Partner, By: Oaktree Fund GP I, L.P. Its: Managing Member. OAKTREE HUNTINGTON INVESTMENT FUND II, L.P., By: Oaktree Huntington Investment Fund II GP, L.P. Its: General Partner, By: Oaktree Fund GP, LLC Its: General Partner, By: Oaktree Fund GP, I, L.P. Its: Managing Member.